|Bid||27.00 x 1300|
|Ask||28.24 x 1200|
|Day's Range||27.00 - 27.20|
|52 Week Range||14.68 - 28.17|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.
Medtronic's (MDT) acquisition of Intersect ENT is intended to offer a wide-ranging variety of solutions to help surgeons treat CRS patients.
Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.